Cogniceuticals improve and treat disorders of attention, learning, memory, or cognition. Cogniceuticals are the fastest growing neuropharmaceutical market for two primary reasons: (1) demographic shifts towards aging population (2) scientific progress on memory related disorders, especially animal models.

As I wrote last year in Saegis a cogniceutical pure play, Saegis continues to prove their cogniceutical focus with their recent announcement that it began a Phase II study of its lead product candidate, SGS742, for adult patients with attention deficit hyperactivity disorder. It's progress and focus like this that have made the neurotechnology industry one of the hottest areas for venture capital investment in the life sciences, surging 225% in the past 5 years.